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1. INTRODUCTION & PURPOSE 
This document details the statistical analysis proposed and the presentation that will be followed, as closely as 
possible, when analysing and reporting the main results from the CAP study (Cluster randomised trial of 
testing for prostate cancer). 
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical practice, and 
that interpretation of a priori and post hoc analyses respectively is appropriate. 
2. Explain in detail how the data will be handled and analyzed to enable others to perform the actual 
analysis in the event of sickness or other absence 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but fall 
outside the scope of this analysis plan (although such analyses would be expected to follow Good Statistical 
Practice). 
The analysis strategy will be made available if required by journal editors or referees when the main 
papers are submitted for publication.  Additional analyses suggested by reviewers or editors will, if considered 
appropriate, be performed in accordance with the Analysis Plan, but if reported the source of such a post-hoc 
analysis will be declared. 
Amendments to the statistical analysis plan will be described and justified in the final report of the trial. 
 
 
2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
The information in this section is extracted from the study protocol (version 7, 29 May 2012) with the single 
purpose of ensuring an informed statistical analysis. For all other purposes reference MUST be made to the 
current version of the protocol. 
2.1. Trial aims and objectives 
To evaluate the effectiveness and cost-effectiveness of population screening for prostate cancer by 
establishing a cluster randomised trial allocating general practices to either intensive case-finding (the ProtecT 
trial) or unscreened standard practice. 
The objectives are: 
1) To provide an unbiased estimate of the effect of a single screen for prostate cancer on prostate cancer-
specific and all-cause mortality in the population. 
2) To contribute to the international effort to investigate the impact of prostate cancer screening. 
3) To estimate the cost implications of prostate cancer screening and use the data collected to develop and 
refine a probabilistic model of the cost-effectiveness of prostate cancer screening in the UK. 
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2.2. Trial design and configuration 
 
 
2.3. Trial centres 
Sheffield, Newcastle, Bristol, Cardiff, Birmingham, Leicester, Cambridge, Leeds. 
2.4. Eligibility criteria 
2.4.1. Inclusion criteria 
Men aged 50 to 69 years, registered at a participating GP practice. All GP practices in the study areas are 
eligible to participate, and are included in the random allocation. 
2.4.2. Exclusion criteria 
Men identified as already having a prostate cancer diagnosis. Men excluded by the study consent process (see 
protocol). 
2.5. Description of interventions 
The intervention is an invitation to PSA testing at a dedicated clinic at or near the man’s GP practice. Those 
men found to have a high PSA level are invited to undergo a diagnostic biopsy. Those men found to have 
clinically localised prostate cancer are invited to have their treatment randomised in the ProtecT trial of 
surgery, radiotherapy, and conservative management. 
 
The comparison is standard NHS practice; GPs discuss the risks and potential benefits with those men 
requesting a PSA test. 
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2.6. Randomisation procedures 
The CaP study is cluster randomised. At each study centre, neighbouring groups of eight to twelve GP practices 
are block-randomised in a 1:1 ratio to PSA testing as part of the ProtecT study, or to NHS usual care in the 
comparison arm. When the group includes an odd number of practices, the greater number are allocated to 
the intervention arm. This randomisation is done by an independent statistician (S Brookes) with no other 
involvement with the study. The randomisation precedes approaches to the GP practices; practices are invited 
to participate in the arm of the study they are allocated to.  
 
Allocation is based on random numbers generated using the contemporary version of Stata statistical software 
(College Station, TX, USA). 
2.8. Blinding 
Members of the cause of death committee see patient vignettes, prepared to obscure the study arm the 
patient is in. Hence decisions about the cause of death is made blind to study arm.  
2.9. Trial committees 
The CaP study has a Data Monitoring Committee (DMC), chairperson Professor Lars Holmberg, which meets 
annually.  The CaP study Cause of Death Committee, chairperson Professor Peter Albertsen. 
2.10. Outcome measures 
2.10.1. Primary outcome 
Prostate cancer mortality at ten years.  
This includes those deaths judged as definitely or probably due to prostate cancer by the cause of death 
committee. Deaths due to the treatment of prostate cancer are included, again as judged by the cause of 
death committee. “Ten years” is be the point in time when the median follow-up period for men in the study is 
ten years; this occurs in 2016. 
2.10.2. Secondary outcomes 
1) All-cause mortality at 5,10 and 15 years 
2) Definite or probable prostate cancer mortality at 5 and 15 years  
3) Disease stage and grade at diagnosis  
4) Cost-effectiveness 
5) Health related Quality of Life 
Health related Quality of Life has been examined in separate sub-studies, and will not be considered further in 
this plan. 
 
2.11. Interim analysis 
Interim analyses by trial arm will be conducted when requested by the DMC. These are prepared by the study 
DMC statistician (C Metcalfe) and shared only with the DMC in the first instance. There are no pre-defined 
formal stopping rules. 
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3. GENERAL ANALYSIS CONSIDERATIONS 
3.1. Analysis populations 
The primary analysis set is all men aged 50 to 69 years registered with a participating practice on the date 
when the patient list is retrieved (the “list date”). Men are excluded as described in Section 2.4.2. 
 
3.2. Derived variables 
 
The primary outcome measure is a binary variable, distinguishing those individuals who definitely or probably 
died of prostate cancer, or treatment for prostate cancer. Time zero is the list date for the man’s GP practice. 
Failure time, or censoring time, is the date on which a man dies, on which the man has left the country, or the 
dataset closure date. 
3.3. Procedures for missing data 
Dates missing the day will be imputed as the 15
th
. 
 
There will be no further imputation of missing data in the primary analysis of clinical effectiveness.  
3.4. Study centre effects 
The primary analysis is adjusted for randomisation cluster. This accommodates any between-centre 
differences in the outcome rate. In addition, differences in the intervention effect by study centre are 
examined as one of the pre-specified subgroup analyses (section 6.5 below). 
3.5. Competing risks 
As age is the only strong risk factor prostate cancer mortality has in common with other causes of death, 
distortion of our results due to “competing risks” is unlikely. 
3.6. Clustering 
 
General practices are the unit of randomisation in this cluster randomised trial. Any resulting variation 
between practices in the men’s outcome rates will be accommodated by separating that variation from that 
between individual men, using practice-level random effects. 
 
4. DESCRIPTION OF PARTICIPANT CHARACTERISTICS 
4.1. Disposition 
The recruitment of GP practices, and the flow of patients through the trial, will be summarised in a CONSORT 
diagram for cluster randomised trials (Campbell, 2004) that includes eligibility, reasons for exclusion, numbers 
randomised to the two intervention groups, losses to follow up and the numbers analysed. 
4.2. Baseline characteristics 
The following comparisons are made between intervention and comparison arm practices, using data from a 
single point in time, which is the earliest point at which this data is reliably available from routine primary care 
statistics: 
 Practice list size 
 IMD score (separately for England and Wales, lower level super output area) 
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 Urban location 
 Prevalence of all cancer 
 Prevalence of diabetes 
 Prevalence of obesity 
 Prevalence of CHD 
Age on list date is the only baseline variable available for individual men, this is compared between the two 
arms of the study using a random effects model. 
 
5. ASSESSMENT OF STUDY QUALITY 
5.1. Eligibility checks 
Patients already diagnosed with prostate cancer on the list date are identified through cancer registry data. 
Details of men are removed from our database as soon as we are aware of their active objection to being 
included in the study. Details of men who are excluded by our consent procedure (see protocol), are not 
transferred from the ProtecT to CaP databases.  
5.2. Data validation  
 
The primary outcome measure is validated by an independent cause of death committee.  
5.3. Study completion 
 
Follow up is passive from each participant’s point of view and consequently follow-up is completed for almost 
all men. One exception is men who emigrate; we are censoring follow-up for these men when we become 
aware of them having emigrated.   
5.4. Compliance 
 
Data are being collected on those intervention arm men who undergo a PSA test as part of the study. 
 
5.5. Protocol deviations 
 
GP practices which do not agree to participate, having been randomised, are excluded from the study and 
analysis. 
 
In an effort to identify comparison arm practices who increase their PSA testing once recruited to the study, 
we will look at when prostate cancer diagnoses occur for each practice. A peak in diagnoses in the period after 
a comparison arm practice joins the study may indicate that practice has been prompted to increase the use of 
PSA testing.  
 
6. ANALYSIS OF EFFECTIVENESS 
6.1. Mis-randomised patients 
 
Patients are analysed according to the allocation of their GP practice. Duplicate records of men who have 
moved practices are removed; if the man moves between arms of the study, the record at the ProtecT practice 
is retained, otherwise the record collected at the earlier date is retained. The number of duplicates and the 
action taken is recorded. 
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6.2. Summary of primary and secondary outcomes 
Definite, probable, and treatment-related prostate cancer mortality are summarised for each study arm as 
Nelson-Aalen cumulative hazard curves, and as 10-year survival (estimated using the Kaplan-Meier method) 
with 95% confidence intervals. 
 
Similar statistics are presented for prostate cancer mortality at other pre-specified time points, and for all-
cause mortality. 
 
Stage and grade at diagnosis are presented as frequency tables, comparing the two arms of the study. 
6.3. Primary analysis 
The null hypothesis for the primary analysis is “no difference in definite, probable and treatment related 
prostate cancer mortality between men at GP practices inviting 50 to 69 year olds to a undergo a single PSA 
test, and men at GP practices following current NHS guidance”. The following Poisson regression model (1) 
incorporates the duration of follow-up for each man i by regressing rates λij on covariates where j is the man’s 
current age group. 
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Variation in outcome between randomisation strata r=1,…,R (neighbouring groups of GP practices) is 
accommodated by standard deviation σr of a level 3, zero mean, normally distributed random effect y0r, and 
variation in outcome between GP practices p=1,…P is accommodated as standard deviation σp  of a level 2 zero 
mean normally distributed random effect. 
 
As the incidence of prostate cancer diagnosis varies greatly by age, each man’s follow-up is divided into the 
following current age-groups according to; a lexis-diagram approach: 59 years or younger, 60-64 years, 65-69 
years, 70-74 years, 75 years or older. With a separate average baseline rate λ0j for each age group j, the 
assumption of a constant baseline rate applies to each group separately and is consequently much more 
reasonable. 
 
The treatment effect is estimated as a rate ratio exp(β1), the coefficient for random allocation xi1 with value 0 
for allocation to the comparison group and value 1 for allocation to the intervention group. 
 
Our initial intention to further divide each man’s follow-up by current calendar period proved problematic for 
estimation and so was abandoned. 
 
It is not anticipated that deaths due to other causes (“competing risks”) will be associated with prostate cancer 
disease, nor will the risk of their recurrence differ between intervention arms. Hence no special measures are 
taken to accommodate bias due to competing risks. 
6.4. Secondary analyses 
The analysis in section 6.3 is adapted to the analysis of other mortality measures. 
 
Analysis of the primary outcome is repeated including definite, probable, possible and treatment-related 
prostate cancer mortality. Similarly, just including definite and treatment-related prostate cancer mortality. 
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6.5. Pre-specified sub-group analyses 
 
Sub-group analyses examine whether the intervention effect varies by age group (50-54, 55-59, 60-64, 65-69+ 
years) at baseline, and by study centre. The evidence against the null hypothesis of equal intervention effect 
across sub-groups is calculated as an interaction test p-value. If the association of  outcome rate and age group 
is consistent with a linear trend, advantage will be taken of this to employ a single degree of freedom 
interaction test, so maximising statistical power. 
6.6. Process analysis 
 
Stage and grade: This analysis focuses on men diagnosed with prostate cancer only. The proportions diagnosed 
over the ten-year average follow-up with Gleason grades 3+3, 3+4, 4+3, 4+4, 4+5, 5+4 and 5+5 is compared 
between study arms using ordered logistic regression. Robust standard errors are employed to allow for 
clustering. This approach is adapted to an analysis of disease stage, based on the TNM system. For this latter 
analysis the patient is classified to the most advanced disease stage applicable from T1, T2, T3, T4, N1, M1. 
 
6.7. Sensitivity analysis 
 
If imbalances are apparent between the participating practices allocated to each study arm, then prior to the 
primary analysis, the study PIs shall list these characteristics for adding as further covariates in the regression 
model. 
Should any of the treatment arms in the ProtecT trial be shown to be superior (i.e. to lead to reduced 
mortality), then any difference in prostate cancer or all-cause mortality between intervention and comparison 
practices will be lower than would be expected if a screening programme had taken place when  the optimal 
treatment(s) were the standard of care. In this case we shall estimate the beneficial effect on mortality of such 
an “optimal” screening programme, based on the (unbiased) treatment effect estimates from the ProtecT trial 
and the (unbiased) overall effect estimates from the CAP study.  
As has been done for the ERSPC study (Schroder 2009; Bokhurst 2013) statistical methods are employed that 
use random allocation as an instrumental variable, to estimate the effect of testing in those who do undergo 
PSA testing (Palmer, 2011). This estimate can be used to predict the overall effect of a screening programme 
under different assumptions about PSA uptake. In contrast to the ERSPC study, we do not attempt to control 
for contamination, due to the very strong assumptions required for this analysis (Metcalfe, 2013). 
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